Arbutus Biopharma (ABUS) Depreciation and Depletion (2015 - 2021)

Arbutus Biopharma has disclosed Depreciation and Depletion across 7 years of filings, most recently posting $427000.0 for Q4 2021.

• Depreciation and Depletion for Q4 2021 came in at $427000.0, down 16.11% year-over-year; the trailing twelve-month figure through Dec 2021 was $1.8 million (down 12.35% YoY), and the FY2025 annual result was $400000.0, down 71.01% from the prior year.
• Depreciation and Depletion came in at $427000.0 for Q4 2021 at Arbutus Biopharma, down from $447000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $620000.0 in Q4 2017 to a low of $334000.0 in Q1 2017.
• The 5-year median for Depreciation and Depletion is $502500.0 (2018), against an average of $499450.0.
• Across the five-year window, Depreciation and Depletion surged 103.78% in 2017 and declined 18.71% in 2018, its largest moves.
• Arbutus Biopharma's Depreciation and Depletion stood at $620000.0 in 2017, then declined by 18.71% to $504000.0 in 2018, then grew by 0.6% to $507000.0 in 2019, then climbed by 0.39% to $509000.0 in 2020, then declined by 16.11% to $427000.0 in 2021.
• The last three Depreciation and Depletion figures came in at $427000.0 (Q4 2021), $447000.0 (Q3 2021), and $436000.0 (Q2 2021), per Business Quant data.